Scynexis (SCYX) EBT Margin Growth (3y) (2016 - 2026)
Powered by 
Analysis
Scynexis (SCYX) EBT Margin Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 443.00 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -15,548.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -484.00 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 132.00 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 6,691.00 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -2,054.00 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 9,980.00 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -2,399.00 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -1.89 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -311,003.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -311,003.00 |
| Dec 31, 2025 | 101,253.00 |
| Sep 30, 2025 | -67,209.00 |
| Jun 30, 2025 | 50,393.00 |
| Mar 31, 2025 | -64,752.00 |
| Dec 31, 2024 | 445,465.00 |
| Sep 30, 2024 | -35,837.00 |
| Mar 31, 2024 | 9,829.00 |
| Jun 30, 2022 | 1.37 Mn |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 905,491.00 |
| Sep 30, 2021 | 999,337.00 |
| Mar 31, 2021 | 1.16 Mn |
| Jun 30, 2019 | -188,429.00 |
| Mar 31, 2019 | -744,219.00 |
| Dec 31, 2018 | -85,469.00 |
| Sep 30, 2018 | 164,375.00 |
| Jun 30, 2018 | -201,875.00 |
| Mar 31, 2018 | -250,820.00 |
| Dec 31, 2017 | -1.12 Mn |